相关实验视频

Updated: May 7, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

通过基于GC-MS的代谢学来阐明洛拉提尼布毒性机制

Di Niu¹, Shiyuan Zhao², Shanshan Kong³

¹Department of Neurosurgery, Jining No.1 People's Hospital, Shandong First Medical University, Jining 272000, China.

Journal of pharmaceutical and biomedical analysis

|June 20, 2025

概括

洛拉提尼布是一种非小细胞肺癌的ALK抑制剂,可能通过破坏脂质,酸,氨酸和氨基酸代谢而引起毒性. 这项研究揭示了洛拉提尼布.

科学领域:

药理学药理学是指药理学的学科.
代谢学代谢学代谢学
毒理学毒理学毒理学

背景情况:

洛拉提尼布是一种第三代ALK抑制剂,有效对抗非小细胞肺癌 (NSCLC).
洛拉提尼布的毒理学概况尚未完全理解.
了解洛拉提尼布的毒性对于患者的安全至关重要.

研究的目的:

用代谢学来研究洛拉提尼布的毒理机制.
在小鼠中识别受洛拉提尼布暴露影响的特定代谢途径.

主要方法:

不针对性代谢进行了小鼠海马体,大脑皮质,肺部和血清.
在对照组和洛拉提尼布治疗组之间确定了不同的代谢物.
对已识别的代谢物进行了KEGG通路丰富分析.

主要成果:

洛拉提尼布暴露改变了多种组织和血清中的代谢物概况.
关键的受损途径包括脂质代谢,酸代谢,尼雅和尼古丁胺代谢以及氨基酸代谢.
在大脑,肺部和全身循环中观察到显著的变化.

结论:

洛拉提尼布的毒性可能源于脂质,氨酸和氨基酸代谢中断.
代谢分析提供了有关洛拉提尼布组织特异性影响的见解.
这项研究阐明了拉提尼布诱导的毒性背后的潜在机制.

关键词:

不同的代谢产物差异化在GC-MS中使用GC-MS.洛拉提尼布 (Lorlatinib) 是一种药物.代谢组中的代谢.鼠标模型模型有毒性有毒性

更多相关视频

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

相关概念视频

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...